Health ❯ Healthcare ❯ Pharmaceuticals

Rare Diseases

Drug Access Lysosomal Storage Disorders Batten Disease Immunology Drug Evaluation Prader-Willi Syndrome Myasthenia Gravis Hematologic Disorders AstraZeneca Portfolio Cortrophin Cortrophin Gel FDA Guidance Heart Conditions Enzyme Replacement Therapy

ANI Pharmaceuticals Posts Record Quarter as Rare-Disease Drugs Power 29.6% Sales Jump

Management reaffirmed 2026 targets, signaling a mid-2026 build-out of its rare-disease commercial team.

FDA Maps New Paths for Rare-Disease Drug Evidence, Keeps Bar High

BioMarin to Acquire Amicus for $4.8 Billion in Cash

China Approves Sanofi’s Qfitlia for Hemophilia A Prophylaxis and Cablivi for aTTP

AstraZeneca Invests $2 Billion to Expand Maryland Biologics and Build New Clinical Site

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline